11:37 AM EDT, 09/03/2024 (MT Newswires) -- Embecta ( EMBC ) said Tuesday it has received the US Food and Drug Administration's 510(k) clearance for disposable patch pump for insulin delivery for the treatment of both type 1 and type 2 diabetes.

The system features a tubeless patch pump with a 300-unit insulin reservoir and a secured controller equipped with Bluetooth technology for a user-friendly interface and experience.

Embecta's ( EMBC ) said its patch pump development program also includes plans to introduce a closed-loop version featuring an insulin-dosing algorithm in a future FDA submission.

Shares of Embecta ( EMBC ) were up 2.3% in recent Tuesday trading.

Price: 16.72, Change: +0.38, Percent Change: +2.33